18 More Reasons to Love This Rule Breaker

The reasons to be bullish on MAKO Surgical (Nasdaq: MAKO  ) keep adding up, and we can now officially add 18 more to the list.

The maker of RIO orthopedic devices has just released selected operating results for its fourth quarter and fiscal 2011, while also giving us a sneak peak of what to expect in the new year. MAKO sold 18 RIO systems in the quarter, 16 of which went to domestic customers. For the full year, 48 RIO systems found new homes, bringing the worldwide commercial installed base to 113.

Growth continues to be the name of the game, with MAKOplasty procedures continuing to soar. MAKOplasty procedures performed in the fourth quarter jumped by 97%, to 2,258, with procedures putting up a 99% rise, to 6,932, for the full year.

Laying the foundation for an entirely new phase of growth, 49 MAKOplasty Total Hip Arthroplasty (THA) applications were sold in the year, of which 37 were sold in the fourth quarter. The new procedure was announced in September, boosting shares since it's a win-win-win for investors, patients, and hospitals alike. It generates an additional revenue source for MAKO, reduces complications associated with conventional hip replacement surgery for patients, and adds another reason for hospitals to buy RIO systems by expanding the care they can provide.

Of its domestic commercial installed base, 44% of systems are now locked and loaded to begin performing MAKOplasty THA procedures.

RIO adoption continues to accelerate, with 2012 expected to move between 56 and 62 systems, higher than the 48 sold in 2011. MAKOplasty procedures tell a similar story, with 11,000 to 13,000 procedures expected to be performed.

I picked up shares in September after we made eyes in August, and there's no other way to put this announcement: This is great progress and definitive confirmation of MAKO's rule-breaking ways. It shares many significant similarities with fellow Foolish favorite Intuitive Surgical (Nasdaq: ISRG  ) , including Intuitive Surgical co-founder and MAKO director Fred Moll. Intuitive Surgical investors who have enjoyed its ride and are looking for their next medical device growth fix should give MAKO some serious consideration. Although it's not profitable yet, MAKO is trending along the path Intuitive set in its early years, and it has a similar model of selling the machines at low margins while collecting high-margin service and disposable-part sales from operating the machines.

It's no wonder that MAKO is so popular among Fools. Colleagues David Meier and Brian Stoffel have joined the MAKO shareholders club recently. Together, we will be looking for MAKO to disrupt incumbents like Zimmer (NYSE: ZMH  ) and Johnson & Johnson (NYSE: JNJ  ) , among others, whose joint replacement solutions may not be the standard of care in the future. Zimmer still looks to replace the total knee, and J&J's DePuy unit, which makes a competing system, landed in hot water less than two years ago over questionable marketing and a recall for its ASR Hip system's failure rate.

Even though shares popped nicely yesterday, this story is far from over, so don't feel like it's too late. With the stock still sitting roughly 27% below its all-time high reached a few short months ago, there's still plenty of time to buy MAKO.

Need even more reading on the future of medical devices? You're in luck, because The Motley Fool has just released a brand-new 100% free report on the next rule-breaking multibagger. Get access to your copy today -- it's free.

Fool contributor Evan Niu owns shares of MAKO Surgical, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Zimmer Holdings, MAKO Surgical, and Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Intuitive Surgical, MAKO Surgical, and Johnson & Johnson. Motley Fool newsletter services have recommended creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (7)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 10, 2012, at 4:32 PM, GordonsGecko wrote:

    Uh oh.... better get Mako!

  • Report this Comment On January 11, 2012, at 5:06 AM, Sbparkinson wrote:

    Mako is no longer a " sleeping giant!"The word is out that it is "on a roll!" Congratulations to their management for " hanging in there!" This is a smaller version of ISRG!

Add your comment.

DocumentId: 1755733, ~/Articles/ArticleHandler.aspx, 7/25/2014 1:06:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement